Sign in to continue:

Sunday, March 29th, 2026

Forian Inc. 2025 Annual Report: Healthcare Data Analytics, Growth Strategies, and Risk Factors Overview

Forian Inc. 2025 Annual Report: Key Highlights and Investor Insights

Forian Inc. 2025 Annual Report: Key Highlights and Investor Insights

Executive Summary

Forian Inc. has released its Annual Report for the fiscal year ended December 31, 2025. The report provides a comprehensive overview of the company’s business operations, financial performance, strategic initiatives, and risk factors. Below, we summarize and analyze the most crucial information that investors and shareholders need to know—including several key disclosures that could potentially impact Forian’s share value.

Company Overview

Forian Inc. is a data and analytics company specializing in healthcare and financial services. The company leverages a proprietary, cloud-based data factory to deliver subscription-based information products, including Real World Evidence (RWE), commercial, and market access solutions. Its products are designed to optimize clinical, operational, and financial outcomes for customers across the fragmented U.S. healthcare landscape.

Key Business Developments

  • Business Strategy: Forian continues to invest heavily in technological innovation, aiming to regularly release new features and upgrades. The company is focused on expanding its data and strategic partner network, with a view to acquiring synergistic assets, products, or companies to enhance its data offerings.
  • Growth Objectives: The company’s strategy includes increasing investment in commercial sales, R&D, and strategic partnerships to drive growth across multiple verticals, including healthcare, media, government, and financial services.
  • Redomiciliation: On January 8, 2026, Forian’s stockholders approved a statutory conversion of the company’s legal domicile from Delaware to Maryland. This redomiciliation may have implications for corporate governance and regulatory oversight.

Financial Performance Highlights (2025 vs. 2024)

  • Interest and Investment Income: \$1.26 million in 2025, down from \$2.42 million in 2024. The decrease was attributed to lower interest rates and a reduced balance of marketable securities following the redemption of convertible notes.
  • Interest Expense: \$142,351 in 2025, a significant decline from \$708,933 in 2024, primarily due to the redemption of convertible notes.
  • Shares Outstanding: As of March 25, 2026, Forian had 31,208,751 shares of common stock outstanding, including unvested restricted stock.

Material Weakness in Internal Control

Important Note: Forian has identified a material weakness in its internal control over financial reporting. As of December 31, 2025, management concluded that disclosure controls and procedures were not effective, and the material weakness could lead to a material misstatement of the company’s financial statements if not timely remediated. The company intends to address these deficiencies but warns that failure to do so could adversely affect the company’s reputation, business, stock price, and result in regulatory investigations.

Risk Factors and Shareholder Considerations

  • Access to Data: Forian depends on external data sources. Loss or restriction of data access could materially impact its ability to deliver products and services.
  • Capital Requirements: The company may need additional capital to fund operations and growth. There is no assurance additional funding will be available, and future equity sales could dilute existing shareholders’ ownership.
  • Volatility of Share Price: The market price of Forian’s common stock may be volatile due to factors such as analyst recommendations, strategic actions, macroeconomic conditions, insider sales, and company performance.
  • Concentration of Ownership: Directors and officers own approximately 24.9% of outstanding shares, giving them significant control over key decisions, which may not always align with the interests of minority shareholders.
  • Dividend Policy: Forian does not intend to pay dividends for the foreseeable future. Returns to shareholders will be limited to stock price appreciation.
  • Emerging Growth Company Status: Forian benefits from reduced reporting requirements under the JOBS Act but warns that this could make its shares less attractive to some investors.
  • Potential for Dilution: Any additional capital raised via equity or convertible debt could dilute existing shareholders and introduce unfavorable terms.
  • Securities Class Action Risk: The company acknowledges the risk of securities class action litigation, especially if the share price declines.
  • Cybersecurity & Data Breach Risk: Forian processes large volumes of data and warns of the risks associated with potential breaches, which could result in legal liability, reputational damage, or material business loss.

Market and Listing Information

  • Exchange: Nasdaq Stock Market (Symbol: FORA)
  • Holders of Record: Approximately 252 as of March 27, 2026 (excluding beneficial holders in street name).
  • Dividend Policy: No cash dividends have been declared or paid; none are planned in the foreseeable future.

Other Noteworthy Disclosures

  • Error Correction: The financial statements included in the 2025 Annual Report reflect the correction of an error in previously issued financial statements.
  • Non-GAAP Measures: The company uses Adjusted EBITDA as a non-GAAP measure to help investors compare performance across companies with different capital structures, but urges caution in relying solely on non-GAAP metrics.
  • Legal Proceedings & Mine Safety Disclosure: No new legal or mine safety disclosures of note.

Forward-Looking Statements and Cautionary Notes

The report contains numerous forward-looking statements regarding Forian’s future plans, product development, business strategy, and anticipated financial results. These are subject to various known and unknown risks, uncertainties, and assumptions—many of which are outside management’s control. New risk factors may emerge, and actual results may differ materially from predictions.

Conclusion: Potential Share Price Sensitivities

Several disclosures in this report are potentially price-sensitive:

  • The identification of a material weakness in internal controls.
  • Ongoing reliance on external data sources and the risk of data access loss.
  • Possible need for additional capital, with risk of shareholder dilution.
  • Recent correction of financial statement errors.
  • Concentration of ownership among insiders and directors.

Shareholders should closely monitor company updates regarding internal control remediation, capital raising activities, and any future changes to its data access agreements or strategic direction.


Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult their financial advisor before making investment decisions. The information is based on Forian’s 2025 Annual Report and may not include all material information relevant to an investment decision.


View Forian Inc. Historical chart here



Semnur Pharmaceuticals, Inc. 2024 Annual Report: Non-Opioid Pain Management Innovations & SP-102 Clinical Results

Semnur Pharmaceuticals, Inc. 2025 Annual Report: Key Highlig...

Silo Pharma Announces $1 Million Share Buyback Program to Enhance Shareholder Value

Silo Pharma Announces Share Buyback Program - Investor Summa...

   Ad